

Anais Del Curatolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2149323/publications.pdf>

Version: 2024-02-01

11
papers

601
citations

1307594

7
h-index

1588992

8
g-index

11
all docs

11
docs citations

11
times ranked

1491
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	8.6	27
2	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	3.3	44
3	Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. Annals of Oncology, 2017, 28, 2896-2898.	1.2	13
4	Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer. Current Medicinal Chemistry, 2017, 24, 1383-1402.	2.4	23
5	PTEN: Multiple Functions in Human Malignant Tumors. Frontiers in Oncology, 2015, 5, 24.	2.8	356
6	Synergistic Growth Inhibitory Activity of Combined Mek/Mtor Pathway Blockade in Pten-Null Cancers. Annals of Oncology, 2014, 25, iv548.	1.2	0
7	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Advances in Biological Regulation, 2014, 56, 66-80.	2.3	77
8	Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. Current Pharmaceutical Design, 2014, 20, 3944-3957.	1.9	55
9	Abstract 803: A vertical combination strategy hitting multiple steps along the MAPK cascade: Molecular mechanisms of action and putative genetic determinants of synergism. , 2014, , .		0
10	Abstract 2618: PTEN loss as a putative biomarker of synergistic growth inhibitory activity of combined MEK/ERK and PI3K/mTOR pathway blockade. , 2014, , .		0
11	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. Expert Opinion on Drug Discovery, 2013, 8, 1381-1397.	5.0	6